Abbott’s FreeStyle Libre 3 CGM Wins CE Mark for People with Diabetes In Europe

Abbott FreeStyle Libre 3 CE Mark
Image: PRNewswire

Abbott announced that its continuous glucose monitor (CGM) the FreeStyle Libre 3 earned a CE mark, making it cleared for use for people with diabetes living in the European Union. This news comes just a few months after the company won the much-awaited U.S. FDA clearance for its FreeStyle Libre 2.

Read more Abbott Receives FDA Approval for Gallant Heart Rhythm Implants Featuring Continuous Remote Monitoring

The FreeStyle Libre 3 technology provides continuous, real-time glucose readings automatically delivered to smartphones every minute, offering unsurpassed 14-day accuracy in the smallest and thinnest sensor design at the same affordable price as previous versions of the device.

“Abbott won’t stop innovating when there’s room to raise the bar. We’ve done that again with FreeStyle Libre 3, the smallest sensor that delivers life-changing benefits and best-in-class accuracy,” said Jared Watkin, senior vice president, Diabetes Care, Abbott. “People living with diabetes are at the center of our design process, and we made our next-generation technology even more discreet for a better user experience to make managing diabetes as easy and seamless as possible.”

The FreeStyle Libre 3 system includes the longest-lasting, self-applied CGM sensor available. The sensor is easy to apply5 with a one-piece applicator and is worn on the back of the upper arm, eliminating the need for painful fingersticks10 to view glucose levels, says a press release, says a press release.

“Since we launched the first disposable glucose sensor in 2014, we’ve always believed all people with diabetes should have access to high-quality, accurate and affordable diabetes technologies,” said Watkin. “That’s why Abbott disrupted the traditional notion that CGMs have to sacrifice quality or accuracy for affordability, and we built our FreeStyle Libre family of products to deliver unparalleled results at a lower cost than any other CGM available.”

Comparing the size of a device against a penny
Image: PRNewswire

The mobile app accompanying FreeStyle Libre 3 is designed to enable users to capture and view their real-time glucose levels, glucose history and trend arrows showing how their glucose is changing with just a glance at their smartphone.

Abbott designed its next-generation FreeStyle Libre 3 system to be more sustainable for the environment with a smaller and more discreet sensor, reducing the total volume by more than 70%.11 With a 41% reduction in plastic use and 43% reduction in carton paper, the new sensor design aligns with the company’s continued commitment to sustainability.

Read more Abbott-Insulet Collaboration to Combine Abbott’s CGM with Insulet’s Omnipod Horizon Automated Insulin Delivery System

Abbott will launch the FreeStyle Libre 3 system in Europe in the coming months. As the #1 sensor-based glucose monitoring system used in the U.S. and worldwide, Abbott’s FreeStyle Libre portfolio has changed the lives of more than 2 million people across more than 50 countries by providing breakthrough technology that is accessible and affordable.

Previous articleAustralian Researchers Develop Brain Implant That May Restore Limited Sight In Blind People
Next articleOCTOBER 2020
Cathy Russey () is Online Editor at WT | Wearable Technologies and specialized in writing about the latest medical wearables and enabling technologies on the market. Cathy can be contacted at info(at)wearable-technologies.com.